IDiyas

For the Inventor, By the Inventor

Carmel, IN, United States of America

Sunil Nagpal

USPTO Granted Patents = 30

Average Co-Inventor Count = 4.9

ph-index = 13

Forward Citations = 874(Granted Patents)


Location History:

  • Irvine, CA (US) (1997 - 2002)
  • Lake Forest, CA (US) (1998 - 2005)
  • Carmel, IN (US) (2003 - 2011)

Company Filing History:

goldMedal10 out of 228 
 
Allergan Sales, Inc.
 patents
silverMedal10 out of 2,285 
 
Allergan, Inc.
 patents
bronzeMedal8 out of 4,442 
 
Eli Lilly and Company
 patents
4. 3 out of 3,682 
 
The Johns Hopkins University
 patents
5. 2 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1997-2011

Loading Chart...
30 patents (USPTO):
1. 7897789 - Vitamin D receptor modulators (2011-03-01),
2. 7772425 - Vitamin D receptor modulators (2010-08-10),
3. 7750184 - Vitamin D receptor modulators (2010-07-06),
4. 7601850 - Phenyl-thiophene type vitamin D receptor modulators (2009-10-13),
5. 7595345 - Vitamin D receptor modulators (2009-09-29),
6. 7582775 - Vitamin D receptor modulators (2009-09-01),
7. 7579488 - Vitamin D receptor modulators (2009-08-25),
8. 7468449 - Phenyl-furan compounds as vitamin D receptor modulators (2008-12-23),
9. 6942980 - Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities (2005-09-13),
10. 6573271 - Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists (2003-06-03),
11. 6521624 - Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities (2003-02-18),
12. 6469028 - Synthesis and use of retinoid compounds having negative hormone and/or anatgonist activities (2002-10-22),
13. 6372753 - Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists (2002-04-16),
14. 6369100 - Method for inhibiting gene expression promoted by AP1 protein with RAR&bgr; selective retinoids and method for treatment of diseases and conditions with such retinoids (2002-04-09),
15. 6294657 - Retinoid induced gene (2001-09-25),

Title: Sunil Nagpal: Innovator in Vitamin D Receptor Modulation

Introduction

Sunil Nagpal, based in Carmel, Indiana, is a prolific inventor with a remarkable portfolio of 30 patents. His work primarily focuses on innovations in vitamin D receptor modulation, offering new therapeutic possibilities for treating bone diseases and psoriasis.

Latest Patents

Sunil's most recent patents include novel, non-secosteroidal phenyl-benzothiophene compounds and diaryl compounds that exhibit vitamin D receptor (VDR) modulating activity. These compounds are designed to be less hypercalcemic than 1α,25 dihydroxy vitamin D3, making them potentially safer and more effective alternatives in treating various conditions related to bone health and skin disorders.

Career Highlights

Throughout his career, Sunil has made significant contributions while working for well-known pharmaceutical companies such as Allergan Sales, Inc. and Allergan, Inc. His innovative spirit and dedication to advancing medical therapeutics have placed him at the forefront of pharmaceutical research.

Collaborations

Sunil has collaborated with esteemed colleagues, including Roshantha A. Chandraratna and Elliott S. Klein. These partnerships have enriched his research endeavors and contributed to the successful development of his patented compounds.

Conclusion

Sunil Nagpal stands out as a key innovator in the field of vitamin D receptor modulation. His extensive patent portfolio reflects his commitment to improving health outcomes through scientific discovery and innovation. As he continues his work, his contributions will undoubtedly have lasting impacts on the treatment of bone diseases and psoriasis.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…